Neopharma and GSK partnership produces first line of medicines packaged in UAE

Partners Neopharma & GSK have produced the first batch of medicines at local Secondary Packaging stage

Neopharma and GSK partnership produces first line of medicines packaged in UAE
  • 35,000 packages of the medicine were manufactured in three months, with plans to have them readily available on shelves for UAE patients in a month

ABU DHABI: Neopharma, a leading global pharmaceutical company based in the United Arab Emirates (UAE) and GlaxoSmithKline (GSK) the global science-led healthcare company, have announced the launch of the first ever locally produced batch of medicines, as a result of their partnership to create localization and manufacturing opportunities in the UAE.

The partnership, announced in April 2019, established Neopharma as GSK’s third-party manufacturer for handling the secondary packaging process (the final manufacturing stage) for six of GSK’s most prescribed medicines in the UAE.

This first batch includes thirty-five thousand packages of medicine, which have been manufactured at Neopharma’s manufacturing plant in Abu Dhabi, with plans to have them readily available for UAE patients in a month.

The launch, which took place at Neopharma’s manufacturing site in Abu Dhabi, was attended by His Excellency Mohamed Al Hameli, Undersecretary of the Department of Health – Abu Dhabi, His Excellency Patrick Moody, the British Ambassador to the United Arab Emirates, Dr B.R. Shetty, Founder and Chairman of Neopharma, Mr. Binay Shetty, Vice Chairman & CEO of BRS Ventures, and Mr.Sameh Elfangary, General Manager for GSK in the Gulf.

His Excellency Mohamed Hamad Al Hameli, Undersecretary of the Department of Health said “Abu Dhabi has set out to become a pharmaceutical research, development and manufacturing hub within the MENA region, and this is another great step forward in achieving this aim. In doing so, the country will be better placed to meet the needs of patients through improved access to locally produced medicines.”

The UK Ambassador to the UAE, His Excellency Mr. Patrick Moody said “The launch is a fantastic example of what UK and UAE companies can achieve together. It is bringing jobs and expertise to the UAE, as well as better services for patients. I congratulate the Abu Dhabi Department of Health and the UK Department for International Trade for their support in making this happen.  It is another step forward in our shared ambition to work together to be global leaders in healthcare and life sciences.” 

Dr B.R. Shetty, Founder and Chairman of Neopharma, said: “It is wonderful to witness another landmark moment in our collaboration with GSK. We are delighted to partner with GSK to be able to provide local patients better access to medicines. By manufacturing the medicine locally, Neopharma has reinforced its commitment to maintaining global quality and manufacturing standards that are complying to stringent regulatory requirements. In innovation science we are focusing on debilitating metabolic diseases, and immuno oncology with over 200 scientists working at Neopharma Japan site. This enable us to deliver innovative and quality products in a timely manner at affordable prices worldwide.

Today Neopharma is proud to be a vertically integrated pharmaceutical company with 10 manufacturing plants spread across USA, Japan, Brazil and India. We manufacture Active Pharmaceutical Ingredients, Oral Finished Dosage Forms, Injectables, Beta Lactams and most of our facilities are approved by USFDA, European Union, ANVISA, PMDA Japan, GCC and other International regulatory authorities.

Sameh Elfangary, General Manager at GSK in the Gulf said “We are delighted to see the outcomes of our partnership with Neopharma already yielding results. As a result of this collaboration, the batch will reach UAE shelves two months earlier than planned. This is the most recent example of GSK’s commitment to ensuring a continuous supply of our high quality, safe, and reliable medicines for patients in the UAE to access.”


About Neopharma

Neopharma LLC, one of the largest pharmaceutical companies in MENA region with 100% subsidiaries in USA, Japan, Brazil, and India. A vertically integrated business, comprising of API, R&D and Formulation facilities in emerging and regulated markets. Neopharma's global presence is supported by 10 manufacturing facilities spread across 4 continents delivering a wide range of branded and generic formulations, active pharmaceutical ingredients (APIs), Contract Research and Manufacturing (CDMO) in the areas of acute and chronic therapies.

Neopharma LLC is a part of the pharmaceuticals vertical of BRS Ventures, UAE’s leading Business House.

For further information, log on to: 

About GSK

GSK is science-led global healthcare company with a special mission-- to help people do more, feel better, live longer. Globally and regionally, we have a proven track-record for providing high quality medicines, vaccines and consumer products. GSK has a 300-year global legacy and more than 70 years of local presence in the Gulf region. Today, GSK is one of the most innovative and best performing companies in the region, providing medical well-being to millions of people in the region.

Neopharma LLC; Tel: +9712 550 1000 

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases